Free tool
FAERS Monitor: Trisenox
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021248 or its brand name (Trisenox, Arsenic Trioxide). Reports on generic versions are filed under their own applications.
Reports
2,284
Serious
2,190
96% of reports
Hospitalization
957
Death reported
303
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- electrocardiogram qt prolonged264
- differentiation syndrome227
- off label use176
- pyrexia107
- pneumonia82
- febrile neutropenia80
- alanine aminotransferase increased79
- dyspnoea75
- neutropenia74
- pleural effusion74
- white blood cell count decreased73
- drug ineffective71
- nausea70
- acute promyelocytic leukaemia differentiation syndrome67
- anaemia66
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 141 |
| 2005 | 110 |
| 2006 | 71 |
| 2007 | 64 |
| 2008 | 83 |
| 2009 | 153 |
| 2010 | 38 |
| 2011 | 98 |
| 2012 | 85 |
| 2013 | 45 |
| 2014 | 80 |
| 2015 | 50 |
| 2016 | 56 |
| 2017 | 67 |
| 2018 | 180 |
| 2019 | 103 |
| 2020 | 113 |
| 2021 | 88 |
| 2022 | 149 |
| 2023 | 125 |
| 2024 | 147 |
| 2025 | 149 |
| 2026 | 89 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,875 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute promyelocytic leukaemia differentiation syndromeSignal | 67 | 4379.8 | 3284.0 | 195,875 |
| differentiation syndromeSignal | 227 | 4126.8 | 3548.2 | 643,931 |
| electrocardiogram qt prolongedSignal | 264 | 68.1 | 60.8 | 17,287 |
| alanine aminotransferase increasedSignal | 79 | 11.9 | 9.6 | 776 |
| pleural effusionSignal | 74 | 11.2 | 9.0 | 679 |
| febrile neutropeniaSignal | 80 | 11.1 | 9.0 | 728 |
| white blood cell count decreasedSignal | 73 | 6.2 | 5.0 | 315 |
| neutropeniaSignal | 74 | 5.0 | 4.0 | 235 |
| anaemiaSignal | 66 | 3.2 | 2.5 | 98 |
| pyrexiaSignal | 107 | 2.8 | 2.4 | 129 |
| pneumoniaSignal | 82 | 2.3 | 1.9 | 62 |
| off label use | 176 | 1.9 | 1.6 | 71 |
| dyspnoea | 75 | 1.2 | 1.0 | 3 |
| nausea | 70 | 0.8 | 0.6 | 3 |
| drug ineffective | 71 | 0.5 | 0.4 | 38 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.